Solid Carcinoma
32
13
17
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.4%
3 terminated out of 32 trials
72.7%
-13.9% vs benchmark
0%
0 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (32)
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
PRE-ISPY Phase I/II Oncology Platform Program
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
A Study of DM001 in Patients With Advanced Solid Tumors
A Study of DM005 in Patients With Advanced Solid Tumors
A Study of DM002 in Patients With Advanced Solid Tumors
Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19
Imaging of Solid Tumors Using 18F-TRX
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
A Study of Avutometinib for People With Solid Tumor Cancers
PET [89Zr]DFO-starPEG in Solid Tumors
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Trop2-targeted immunoPET Imaging of Solid Tumors
Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk
FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy